Lentitek, the Edinburgh-based biotech company who are revolutionising viral vector technology for next generation CAR-T cell and gene therapies, recently secured a further investment of £700k from Equity Gap and other existing investors including Gabriel Investment Syndicate, Apollo Informal Investments and Scottish Enterprise.
Thanks to Insider.co.uk, Scottish Financial Review, Daily Business, The Scotsman, Deadline News, Scottish Financial News and The Microbiologist (so far) for sharing the news!